Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

Olivier Loeillot President and Chief Commercial Officer WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences

Related Keywords

Massachusetts ,United States ,Netherlands ,Waltham ,Ireland ,Estonia ,Singapore ,Germany ,Sweden ,France ,Sondras Newman ,Cytivaa Danaher ,Olivier Loeillot ,Master Of Business Administration ,Repligen Corporation ,European High Institute Of Chemistry ,Ge Healthcare Life Sciences ,Exchange Commission ,Cellular Research ,Business School ,Linkedin ,Enterprise Solutions ,Chief Commercial Officer ,Bioprocess President ,Vice President Sales ,Lonza Custom ,Chief Executive Officer ,Ascensus Specialties ,Vice President ,Custom Manufacturing Business ,Microbial Biopharmaceuticals ,European High Institute ,Business Administration ,Fluid Management ,Process Analytics ,Xlife Sciences Company ,Repligen ,Bioprocessing ,Onza Custom Manufacturing ,Executive Team ,